4 stories mentioning ASX:ATXUpdated 8m ago
Every FINWIRES story that references ASX:ATX, newest first.
Amplia Therapeutics (ASX:ATX) received notice that Washington H. Soul Pattinson (ASX:SOL) and its subsidiaries became substantial holders of the company on Monday, according to a Thursday Australian bourse filing.Washington H. Soul Pattinson now owns 27.5 million shares in the company, representing a 5.37% total voting power, the filing said.
Amplia Therapeutics (ASX:ATX) said Pengana Capital became a substantial holder in the company on June 22 with a stake of 5.37% or 27.5 million shares, according to a Wednesday Australian bourse filing.
Amplia Therapeutics (ASX:ATX) is initiating a phase 2b study of its narmafotinib drug candidate in combination with chemotherapies gemcitabine and Abraxane in newly diagnosed advanced pancreatic cancer patients to explore a new dosing regimen, according to a Tuesday Australian bourse filing.Each dosing group will have six patients, which will be combined with gemcitabine and Abraxane given on their conventional schedule, the filing said. The study will assess safety and tolerability, pharmacokinetics, and efficacy. Exploratory endpoints will include effects on disease biomarkers as well as effects on fibrosis.The study, designed in alignment with US Food and Drug Administration feedback, will enroll patients across three to four sites in Australia starting in the fourth quarter, per the filing. It will form the first stage of a registrational study in this indication.
Amplia Therapeutics (ASX:ATX) reached an agreement with the Australia New Zealand Gynaecological Oncology Group, or ANZGOG, to perform a clinical study evaluating Amplia's narmafotinib lead drug candidate in ovarian cancer, according to a Friday filing with the Australian bourse.Narmafotinib is in development for pancreatic cancer, where it has demonstrated "promising efficacy combined with good tolerability," the company said.The new study is expected to enroll about 15 to 20 patients with high-grade serous ovarian cancer to investigate narmafotinib's safety in combination with standard-of-care chemotherapy.
